

Organized by



Grupo Español de Cáncer de Pulmón
Spanish Lung Cancer Group

9th Congress on Lung Cancer

Barcelona, November 17th and 18th, 2011

Registrations: www.doctaforum.com/gecp

Under the Auspices of:

SEOM
Sociedad Española
de Oncología Médica

ESMO GOOD SCIENCE
BETTER MEDICINE
BEST PRACTICE
European Society for Medical Oncology

Thursday, 17th November 2011

SESSION 1 - Early NSCLC

CHAIRS: Florentino Hernando-Trancho, *Hospital Clínico Univ. San Carlos, Madrid*
Miquel Tarón, *ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona)*

10:30 - 10:35

Introduction

Miquel Tarón
ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona)

10:35 - 10:50

Predictive gene signature

Ramón García-Escudero
Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Madrid

10:50 - 11:05

Gene signatures in early NSCLC

Miquel Tarón
ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona)

11:05 - 11:20

Modern approaches to customizing adjuvant chemotherapy

Michel van den Heuvel
Netherlands Thoracic Institute -Antoni van Leeuwenhoek Hospital, Amsterdam, Holland

11:20 - 11:35

Molecular analysis of survival signaling pathways from the NATCH trial: A Trans-Athlantic Collaboration

Fadlo R. Khuri
Emory University, Atlanta (Georgia), USA

11:35 - 11:40

Conclusions

Florentino Hernando-Trancho
Hospital Clínico Univ. San Carlos, Madrid

SESSION 2 -

Pathology and Lung Cancer Biology

CHAIRS: Susana Benlloch, *USP Institut Dexeus, Pangaea Biotech, Barcelona*
Javier de Castro, *Hospital Univ. La Paz, Madrid*

11:40 - 11:45

Introduction: relevance of translational research

Javier de Castro
Hospital Univ. La Paz, Madrid

11:45 - 12:00

Molecular advances in lung cancer pathology

Santiago Ramón y Cajal
Hospital Univ. Vall d'Hebron, Barcelona

12:00 - 12:15

BRAF mutations in NSCLC

Antonio Marchetti
University-Foundation, Chiety, Italy

12:15 - 12:30

ALK, LKB1 and P130 assessment

M^a Luisa Botero
USP Institut Dexeus, Pangaea Biotech, Barcelona

12:30 - 12:45

ALK translocations, PIK3CA amplification

Miguel A. Molina
USP Institut Dexeus, Pangaea Biotech, Barcelona

12:45 - 13:00

The future role of pathologists in translational research

Massimo Rugge
University of Padua, Padua, Italy

Barcelona, November 17th and 18th, 2011

- 13:00 - 13:15** **Endothelial circulating cells and microparticles in lung cancer**
Tania C. Fleitas
Hospital Univ. La Fe, Valencia
- 13:15 - 14:15* *Lunch*
- SESSION 3 - Discoveries in Cancer Biology**
CHAIRS: **Montserrat Sánchez-Céspedes, Instituto de Investigación Biomédica de Bellvitge, Hospital Duran i Reynals, L'Hospitalet de Llobregat (Barcelona)**
Miquel Tarón, ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona)
- 14:15 - 14:30** **Mutation screening and biological characterization of BRG1 and other tumor suppressor genes in lung cancer**
Montserrat Sánchez-Céspedes
Instituto de Investigación Biomédica de Bellvitge, Hospital Duran i Reynals, L'Hospitalet de Llobregat (Barcelona)
- 14:30 - 14:45** **Keynote Lecture: NF- κ B in FAS signaling pathway in tumors with EGFR mutations**
Trevor G. Bivona
University of San Francisco, California, USA
- 14:45 - 15:15** **Genes involved in chromatin remodeling complex as determinants of sensitivity to ALK and EGFR inhibitors**
René Bernards
Het Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, Holland
- 15:15 - 15:30** **AEG-1 and BRCA1 as determinants of outcome to erlotinib in EGFR-mutated NSCLC**
Miquel Tarón
ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona)
- 15:30 - 15:45** **Keynote Lecture: FGFR1 amplification and other targetable alterations in squamous cell carcinoma**
Roman Thomas
Dana Farber Cancer Institute, Harvard Medical School, Boston (Massachusetts), USA
- 15:45 - 16:00* *Break*
- SESSION 4 - Customized Clinical Trials**
CHAIRS: **Carlos Camps, Hospital General Universitario, Valencia**
Bartomeu Massutí, Hospital General Universitario, Alicante
- Introduction**
Bartomeu Massutí
Hospital General Universitario, Alicante
- 16:00 - 16:15** **EURTAC**
Luis Paz-Ares
Hospital Univ. Virgen del Rocío, Sevilla
- 16:15 - 16:30** **SCAT**
José M. Sánchez
Centro Oncológico M.D. Anderson International España, Madrid
- 16:30 - 16:45** **BREC**
Carlos Camps
Hospital General Universitario, Valencia
- 16:45 - 17:00** **BREC-China**
Jia Wei
Drum Tower Hospital, Nanjing, China

17:00 - 17:15 **Olaparib+gefitinib**
Rosario García-Campelo
Complejo Hospitalario Universitario, A Coruña

17:15 - 17:30 **Bevacizumab**
Oliver Gautschi
Bern University Hospital, Bern, Switzerland

17:30 - 17:55 *Coffee Break*

CLINICAL WORKSHOP

CHAIRS: Carlos Camps, *Hospital General Universitario, Valencia*
Manuel Dómine, *Fundación Jiménez Díaz, Madrid*
Dolores Isla, *Hospital Clínico Univ. Lozano Blesa, Zaragoza*

17:55 - 18:05 **Lung cancer in never-smokers: differential issues**
José M. Trigo
Hospital Clínico Univ. Virgen de la Victoria, Málaga

18:05 - 18:15 **Different endpoints with targeted therapies**
Manuel Cobo
Hospital Univ. Carlos Haya, Málaga

18:15 - 18:25 **Optimal techniques for early detection of response**
Alfredo Sánchez
Hospital Provincial de Castellón, Castellón

18:25 - 18:35 **New drugs, new toxicities**
Ruth Porta
ICO, Hospital Univ. Dr. Josep Trueta, Girona

18:35 - 18:45 **Treatment strategy for advanced squamous carcinoma**
Margarita Majem
Hospital de la Santa Creu i Sant Pau, Barcelona

18:45 - 18:55 **Selection of patients for maintenance treatment**
Ana Blasco
Hospital General Universitario, Valencia

18:55 - 19:05 **Treatment for patients resistant to EGFR-TKIs**
Ramón Palmero
ICO, Hospital Duran i Reynals, L'Hospitalet de Llobregat (Barcelona)

19:05 - 19:15 **The REASON study**
Bartomeu Massutí
Hospital General Universitario, Alicante

19:15 - 19:25 **Discussion**
Carlos Camps, *Hospital General Universitario, Valencia*
Manuel Dómine, *Fundación Jiménez Díaz, Madrid*
Dolores Isla, *Hospital Clínico Univ. Lozano Blesa*

Friday, 18th November 2011

08:00 - 08:30 **SLCG Plenary Session**

08:30 - 09:00 **Plenary Lecture**

Rafael Rosell

ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona)

SESSION 5 - Applicability of Translational Research

CHAIRS:

Adolfo G. Favaretto, *University Hospital, Padua, Italy*

Miquel Tarón, *ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona)*

09:00 - 09:15 **mRNA expression of genes involved in the EGFR and NF- κ B pathways**

Santiago Viteri

USP, Institut Dexeus, Barcelona

09:15 - 09:30 **NF- κ B inhibitors and RAS signalling**

Haian Fu

Emory University, Atlanta (Georgia), USA

09:30 - 09:45 **The refined BRCA1 model in cisplatin-treated patients**

Laura Bonanno

University of Padua, Padua, Italy

09:45 - 10:00 **Circulating tumor cells**

Andreas-Claudius Hoffmann

West German Cancer Center, Essen, Germany

10:00 - 10:15 **EGFR in Latin America**

Andrés F. Cardona

Centro Javeriano de Oncología, Bogotá, Colombia

10:15 - 10:30 **The TOFEM registry**

Margarita Majem

Hospital de la Santa Creu i Sant Pau, Barcelona

10:30 - 10:45 **Molecular predictive markers for response to bevacizumab:**

the role of the AMP kinase pathway

Stefano Indraccolo

Istituto Oncologico Veneto - IRCCS, Padua, Italy

10:45 - 11:05 *Coffee Break*

SESSION 6 - Chemoradiotherapy

CHAIRS:

Wilfried Eberhardt, *West German Cancer Center, Essen, Germany*

Ferran Guedea, *Institut Català d'Oncologia, L'Hospitalet de Llobregat (Barcelona)*

11:05 - 11:20 **Trimodality in stage III NSCLC**

Wilfried Eberhardt

West German Cancer Center, Essen, Germany

11:20 - 11:35 **Progress in chemoradiotherapy studies**

Pilar Garrido

Hospital Univ. Ramón y Cajal, Madrid

11:35 - 11:50 **Potential role for customized and targeted therapies in the NSCLC neoadjuvant setting**

Diego Márquez-Medina

Hospital Arnau de Vilanova, Lleida

- 11:50 - 12:05** **Translational research in stage III NSCLC**
Joana Spiekermann
West German Cancer Center, Essen, Germany
- 12:05 - 12:15** **Conclusions**
Josep Jové
ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona)
- SESSION 7 - SCLC**
CHAIR: Manuel Dómine, *Fundación Jiménez Díaz, Madrid*
- 12:15 - 12:30** **Optimal approach for limited disease**
Corinne Finn
The Christie NHS Foundation Trust, Manchester, United Kingdom
- 12:30 - 12:45** **Treatment of metastatic SCLC**
Fiona H. Blackhall
The Christie NHS Foundation Trust, Manchester, United Kingdom
- 12:45 - 13:00** **Molecular research in SCLC: an empty field?**
Luciano Wannesson
Oncology Institute of Southern Switzerland, Bellinzona, Switerland
- 13:00 - 13:15** **Conclusions**
Manuel Dómine
Fundación Jiménez Díaz, Madrid
- SESSION 8 - Special Cases**
CHAIRS: Rolf A. Stahel, *University Hospital, Zurich, Switzerland*
Alain Vergnenègre, *Cluzeau University Hospital, Limoges, France*
- 13:15 - 13:30** **Mesothelioma: state of the art and projects**
Rolf A. Stahel
University Hospital, Zurich, Switzerland
- 13:30 - 13:45** **Molecular research in mesothelioma: an empty field?**
Enric Carcereny
ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona)
- 13:45 - 14:00** **Management of elderly patients**
Alain Vergnenègre
Cluzeau University Hospital, Limoges, France
- 14:00 - 15:00** *Lunch*
- SESSION 9 - Targeted Therapies and Novel Agents**
CHAIRS: Fernando Barata, *Centro Hospitalario Coimbra, Coimbra, Portugal*
Felipe Cardenal, *ICO, Hospital Duran i Reynals, L'Hospitalet de Llobregat (Barcelona)*
- Introduction**
Felipe Cardenal
ICO, Hospital Duran i Reynals, L'Hospitalet de Llobregat (Barcelona)
- 15:00 - 15:15** **State of the art of clinical trials with novel agents**
Enriqueta Felip
Hospital Univ. Vall d'Hebron, Barcelona
- 15:15 - 15:30** **The role of the ETOP in clinical trials**
Rolf A. Stahel
University Hospital, Zurich, Switzerland

- 15:30 - 15:40** **Cost-efficacy management in the use of EGFR TKIs**
Ana Clopés
ICO, Hospital Duran i Reynals, L'Hospitalet de Llobregat (Barcelona)
- 15:40 - 15:50** **Conclusions**
Fernando Barata
Centro Hospitalario Coimbra, Coimbra, Portugal
- SESSION 10 - SLCG Clinical Trials**
CHAIRS: Enric Carcereny, *ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona)*
Alain Vergnenègre, *Cluzeau University Hospital, Limoges, France*
- 15:50 - 16:00** **PHALCIS**
José M. Sánchez
Centro Oncológico M.D. Anderson International España, Madrid
- 16:00 - 16:10** **ANGIOMET**
Eloísa Jantus
Hospital General Universitario, Valencia
- 16:10 - 16:30** **TARZO**
Noemí Reguart
Hospital Clínic Universitari, Barcelona
- 16:30 - 16:40** **RENO**
Mariano Provencio
Hospital Univ. Puerta de Hierro, Majadahonda (Madrid)
- 16:40 - 17:00** **LUNGSCAPE**
Fiona H. Blackhall
The Christie NHS Foundation Trust, Manchester, United Kingdom
Keith Kerr
Aberdeen University Medical School, Aberdeen, United Kingdom

Venue

Hotel Meliá Barcelona
50 Sarriá Av.
08029 Barcelona (Spain)

Language

Lectures will be delivered in English or Spanish

Organizing & Scientific Committee

Carlos Camps, *Hospital General Universitario, Valencia*
Felipe Cardenal, *ICO, Hospital Duran i Reynals, L'Hospitalet de Llobregat (Barcelona)*
Javier de Castro, *Hospital Universitario La Paz, Madrid*
Manuel Cobo, *Hospital Universitario Carlos Haya, Málaga*
Manuel Dómine, *Fundación Jiménez Díaz, Madrid*
Rosario García Campelo, *Complejo Hospitalario Universitario, A Coruña*
Florentino Hernando Trancho, *Hospital Clínico Universitario San Carlos, Madrid*
Dolores Isla, *Hospital Clínico Universitario Lozano Blesa, Zaragoza*
Eloisa Jantús, *Hospital General Universitario, Valencia*
Margarita Majem, *Hospital de la Santa Creu i Sant Pau, Barcelona*
Bartomeu Massutí, *Hospital General Universitario, Alicante*
Luis Paz Ares, *Hospital Universitario Virgen del Rocío, Seville*
Mariano Provencio, *Hospital Universitario Puerta de Hierro Majadahonda (Madrid)*
Noemí Reguart, *Hospital Clínic Universitari, Barcelona*
Rafael Rosell, *ICO, Hospital Universitario Germans Trias i Pujol, Badalona (Barcelona)*
José Javier Sánchez, *Universidad Autónoma de Madrid*
José Miguel Sánchez, *Centro Oncológico MD Anderson International, Madrid*
Miquel Taron, *ICO, Hospital Universitario Germans Trias i Pujol, Badalona (Barcelona)*

Credits

Accredited by the European Society for Medical Oncology Educational Committee Working Group for its medical oncology certification approval program with 13 ESMO-MORA category 1 points.

Accreditation requested to the "Consell Català de Formació Continuada de les Professions Sanitàries"

Supporting Companies

Conference Secretariat

Doctaforum · Congresos y Reuniones Científicas
Monasterios de Suso y Yuso 34, 4-14-2 · 28049 Madrid
Tel.: +34 91 372 02 03 · Fax: +34 91 735 04 54
www.doctaforum.com/gecp